Novartis Danmark company information, Employees & Contact Information

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis

Novartis Pharma AG Via Ritzau

Novartis Pharma AG Via Ritzau

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer Novartis

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront Novartis

Novartis Pharma AG Via Ritzau

Novartis Pharma AG Via Ritzau

Novartis Pharma AG Via Ritzau

Our commitment to ethical and responsible use of Artificial Intelligence (AI) Novartis

Research and development Novartis

Payments to Healthcare Professionals Novartis

Global Health disease area research at Novartis Novartis

Research disease areas Novartis

Immunology disease research at Novartis Novartis

Therapeutic areas Novartis

Managed access programs Novartis

Early careers Novartis

Coronavirus Novartis

Cardiovascular, renal and metabolic Novartis

Neuroscience research at Novartis Novartis

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) Novartis

Cardiovascular and metabolic disease research at Novartis Novartis

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline Novartis

Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma Novartis

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer Novartis

People and culture Novartis

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer Novartis

Novartis access principles Novartis

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) Novartis

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA Novartis

Sickle cell disease Novartis

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) Novartis

Climate Novartis

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Novartis

Board of Directors Novartis

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off Novartis

FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS) Novartis

Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness Novartis

Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria Novartis

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease Novartis

About Novartis

Novartis to sell its Roche stake in a bilateral transaction to Roche Novartis

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran) Novartis

Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss Novartis

Achieving 100% renewable electricity Novartis

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms Novartis

Novartis provides update on production of radioligand therapy medicines Novartis

Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off Novartis

Novartis expands alliance with Science 37 to advance virtual clinical trials program Novartis

Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader Novartis

Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis Novartis

Product sales Novartis

Bringing virtual reality to the lab Novartis

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Novartis

Fixed-income securities Novartis

Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities Novartis

Novartis expands its biopharmaceutical manufacturing site in Singapore Novartis